The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancer

References

• NagaiahGHossainAMooneyCJParmentierJRemickSCAnaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatmentJ Oncol2011201154235821772843
   PubMedGoogle Scholar
• NikiforovaMNNikiforovYEMolecular diagnostics and predictors in thyroid cancerThyroid200919121351136119895341
   PubMed Web of Science ®Google Scholar
• SmallridgeRCMarlowLACoplandJAAnaplastic thyroid cancer: molecular pathogenesis and emerging therapiesEndocr Relat Cancer2009161174418987168
   PubMed Web of Science ®Google Scholar
• BibleKCSmallridgeRCMorrisJCDevelopment of a multidisciplinary, multicampus subspecialty practice in endocrine cancersJ Oncol Pract20128Suppl 3e1se5s22942830
   PubMedGoogle Scholar
• XingMGenetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancerThyroid201020769770620578891
   PubMed Web of Science ®Google Scholar
• García-RostánGCostaAMPereira-CastroIMutation of the PIK3CA gene in anaplastic thyroid cancerCancer Res20056522101991020716288007
   PubMed Web of Science ®Google Scholar
• SantarpiaLEl-NaggarAKCoteGJMyersJNShermanSIPhosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancerJ Clin Endocrinol Metab200893127828417989125
   PubMed Web of Science ®Google Scholar
• LiuDXingMPotent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathwaysThyroid200818885386418651802
   PubMed Web of Science ®Google Scholar
• UlisseSDelcrosJGBaldiniETollerMExpression of Aurora genes kinases in human thyroid carcinoma cell lines and tissuesInt J Cancer2006119227528216477625
   PubMed Web of Science ®Google Scholar
• KimJHLeeperRDTreatment of anaplastic giant and spindle cell carcinoma of the thyroid gland with combination adriamycin and radiation therapy. A new approachCancer19835269549576883279
   PubMed Web of Science ®Google Scholar
• De BesiPBusnardoBTosoSCombined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancerJ Endocrinol Invest19911464754801723086
   PubMed Web of Science ®Google Scholar
• VoigtWBulankinAMullerTSchedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell linesClin Cancer Res2000652087209310815936
   PubMed Web of Science ®Google Scholar
• PushkarevVMStarenkiDVSaenkoVAMolecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cellsEndocrinology200414573143315215044368
   PubMed Web of Science ®Google Scholar
• AinKBEgorinMJDeSimonePATreatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) GroupThyroid200010758759410958311
   PubMed Web of Science ®Google Scholar
• HigashiyamaTItoYHirokawaMInduction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinomaThyroid201020171420025538
   PubMed Web of Science ®Google Scholar
• CatalanoMGPoliRPuglieseMFortunatiNBoccuzziGValproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell linesEndocr Relat Cancer200714383984517914112
   PubMed Web of Science ®Google Scholar
• VoigtWKegelTWeissMMuellerTSimonHSchmollHJPotential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinomaJ Cancer Res Clin Oncol2005131958559016021466
   PubMed Web of Science ®Google Scholar
• ShimaokaKSchoenfeldDADeWysWDCreechRHDeContiRA randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinomaCancer1985569215522213902203
   PubMed Web of Science ®Google Scholar
• WangSLloydRVHutzlerMJSafranMSPatwardhanNAKhanAThe role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancerMod Pathol200013888288710955455
   PubMed Web of Science ®Google Scholar
• WangYTsangRAsaSDicksonBArenovichTBrierleyJClinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimensCancer200610781786179216967442
   PubMed Web of Science ®Google Scholar
• HaighPIItuartePHWuHSCompletely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survivalCancer200191122335234211413523
   PubMed Web of Science ®Google Scholar
• BrignardelloEGalloMBaldiIAnaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 yearsEur J Endocrinol2007156442543017389456
   PubMed Web of Science ®Google Scholar
• VoutilainenPEMultanenMHaapiainenRKLeppaniemiAKSivulaAHAnaplastic thyroid carcinoma survivalWorld J Surg1999239975978 discussion 978–979.10449831
   PubMed Web of Science ®Google Scholar
• TanRKFinleyRKIIIDriscollDBakamjianVHicksWLJrSheddDPAnaplastic carcinoma of the thyroid: a 24-year experienceHead Neck1995114147 discussion 47–48.7883548
   PubMed Web of Science ®Google Scholar
• VenessMJPorterGSMorganGJAnaplastic thyroid carcinoma: dismal outcome despite current treatment approachANZ J Surg200474755956215230790
   PubMed Web of Science ®Google Scholar
• SchlumbergerMParmentierCDelisleMJCouetteJEDrozJPSarrazinDCombination therapy for anaplastic giant cell thyroid carcinomaCancer19916735645661985750
   PubMed Web of Science ®Google Scholar
• MitchellGHuddartRHarmerCPhase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinomaRadiother Oncol1999501333810225555
   PubMed Web of Science ®Google Scholar
• BesicNAuerspergMUs-KrasovecMGolouhRFrkovic-GrazioSVodnikAEffect of primary treatment on survival in anaplastic thyroid carcinomaEur J Surg Oncol200127326026411373102
   PubMed Web of Science ®Google Scholar
• De CrevoisierRBaudinEBachelotACombined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapyInt J Radiat Oncol Biol Phys20046041137114315519785
   PubMed Web of Science ®Google Scholar
• KobayashiTAsakawaHUmeshitaKTreatment of 37 patients with anaplastic carcinoma of the thyroidHead Neck199618136418774920
   PubMed Web of Science ®Google Scholar
• Swaak-KragtenATde WiltJHSchmitzPIBontenbalMLevendagPCMultimodality treatment for anaplastic thyroid carcinoma – treatment outcome in 75 patientsRadiother Oncol200992110010419328572
   PubMed Web of Science ®Google Scholar
• VrbicSPejcicIVrbicMFilipovicSTherapy of stage IV B anaplastic thyroid carcinoma: single institution experienceJ BUON2009141414419373945
   PubMed Web of Science ®Google Scholar
• YauTLoCYEpsteinRJLamAKWanKYLangBHTreatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapyAnn Surg Oncol20081592500250518581185
   PubMed Web of Science ®Google Scholar
• LimSMShinSJChungWYTreatment outcome of patients with anaplastic thyroid cancer: a single center experienceYonsei Med J201253235235722318823
   PubMed Web of Science ®Google Scholar
• LeeJJFoukakisTHashemiJMolecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma modelsThyroid200717428930117465858
   PubMed Web of Science ®Google Scholar
• McIverBHayIDGiuffridaDFAnaplastic thyroid carcinoma: a 50-year experience at a single institutionSurgery200113061028103411742333
   PubMed Web of Science ®Google Scholar
• AkaishiJSuginoKKitagawaWPrognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinomaThyroid201121111183118921936674
   PubMed Web of Science ®Google Scholar
• HeronDEKarimpourSGrigsbyPWAnaplastic thyroid carcinoma: comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groupsAm J Clin Oncol200225544244612393980
   PubMed Web of Science ®Google Scholar
• NilssonOLindebergJZedeniusJAnaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year periodWorld J Surg19982277257309606289
   PubMed Web of Science ®Google Scholar
• TennvallJLundellGWahlbergPAnaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgeryBr J Cancer200286121848185312085174
   PubMed Web of Science ®Google Scholar
• JunorEJPaulJReedNSAnaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapyEur J Surg Oncol199218283881582515
   PubMed Web of Science ®Google Scholar
• LevendagPCDe PorrePMvan PuttenWLAnaplastic carcinoma of the thyroid gland treated by radiation therapyIntl J Radiat Oncol Biol Phys199326125128
   Web of Science ®Google Scholar
• DerbelOLimemSSégura-FerlayCResults of combined treatment of anaplastic thyroid carcinoma (ATC)BMC Cancer20111146922044775
   PubMed Web of Science ®Google Scholar
• KimSSchiffBAYigitbasiOGTargeted molecular therapy of anaplastic thyroid carcinoma with AEE788Mol Cancer Ther20054463264015827337
   PubMed Web of Science ®Google Scholar
• NobuharaYOnodaNYamashitaYEfficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell linesBr J Cancer20059261110111615785737
   PubMed Web of Science ®Google Scholar
• KurebayashiJOkuboSYamamotoYAdditive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cellsCancer Chemother Pharmacol200658446047016435154
   PubMed Web of Science ®Google Scholar
• HoffmannSBurchertAWunderlichADifferential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell linesEndocrine20073110511317873319
   PubMed Web of Science ®Google Scholar
• PodtchekoAOhtsuruATsudaSThe selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cellsJ Clin Endocrinol Metab2003881889189612679488
   PubMed Web of Science ®Google Scholar
• BlagosklonnyMVGiannakakouPWojtowiczMEffects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cellsJ Clin Endocrinol Metab199883251625229661637
   PubMed Web of Science ®Google Scholar
• BonofiglioDQiHGabrieleSPeroxisome proliferator activated receptor γ inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent mannerEndocr Relat Cancer200815254555718509005
   PubMed Web of Science ®Google Scholar
• FuryMGSolitDBSuYBA phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumorsCancer Chemother Pharmacol20075946747516896930
   PubMed Web of Science ®Google Scholar
• CohenEEWRosenLSVokesEEAxitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II studyJ Clin Oncol2008264708471318541897
   PubMed Web of Science ®Google Scholar
• Gupta-AbramsonVTroxelABNelloreAPhase II trial of sorafenib in advanced thyroid cancerJ Clin Oncol200826294714471918541894
   PubMed Web of Science ®Google Scholar
• ChoKWangXNieSChenZGShinDMTherapeutic nanoparticles for drug delivery in cancerClin Cancer Res2008141310131618316549
   PubMed Web of Science ®Google Scholar
• AtadjaPDevelopment of the pan-DAC inhibitor panobinostat (LBH589): successes and challengesCancer Lett2009280223324119344997
   PubMed Web of Science ®Google Scholar
• GuleMKChenYSanoDTargeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine modelClin Cancer Res20111782281229121220477
   PubMed Web of Science ®Google Scholar
• WunderlichARothSRamaswamyACombined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancerEndocrine201242363764622477151
   PubMed Web of Science ®Google Scholar
• SpallanzaniABertoliniFDepenniRTyrosine kinase inhibitors (TKIs) in advanced thyroid cancer: a single institution reportSupplementi di Tumori2012133S99
   Google Scholar
• RosoveMHPeddiPFGlaspyJABRAF V600E inhibition in anaplastic thyroid cancerN Engl J Med2013368768468523406047
   PubMed Web of Science ®Google Scholar
• NehsMANuceraCNagarkattiSSLate intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancerEndocrinology201215398599422202162
   PubMed Web of Science ®Google Scholar
• BrownRFDucicYAggressive surgical resection of anaplastic thyroid carcinoma may provide long-term survival in selected patientsOtolaryngol Head Neck Surg2013148456457123396588
   PubMed Web of Science ®Google Scholar
• SunXSSunSRGuevaraNChemoradiation in anaplastic thyroid carcinomasCrit Rev Oncol Hematol201286329030123218594
   PubMed Web of Science ®Google Scholar
• DeshpandeHARomanSSosaJANew targeted therapies and other advances in the management of anaplastic thyroid cancerCurr Opin Oncol2013251444923159847
   PubMed Web of Science ®Google Scholar
• PaciniFCastagnaMGBrilliLPentheroudakisGESMO Guidelines Working GroupThyroid Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201223Suppl 7vii110vii11922997443
   PubMed Web of Science ®Google Scholar
• XingMBRAF mutation in thyroid cancerEndocr Relat Cancer200512224526215947100
   PubMed Web of Science ®Google Scholar
• HouPLiuDShanYGenetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancerClin Cancer Res20071341161117017317825
   PubMed Web of Science ®Google Scholar
• LiuZHouPJiMGuanHHighly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancersJ Clin Endocrinol Metab20089383106311618492751
   PubMed Web of Science ®Google Scholar
• CaroniaLMPhayJEShahMHRole of BRAF in thyroid oncogenesisClin Cancer Res201117247511751721900390
   PubMed Web of Science ®Google Scholar
• Ricarte-FilhoJCRyderMChitaleDAMutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1Cancer Res200969114885489319487299
   PubMed Web of Science ®Google Scholar
• NehsMANagarkattiSNuceraCHodinRAParangiSThyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancerSurgery2010148611541162 discussion 1162.21134546
   PubMed Web of Science ®Google Scholar
• SavvidesPNagaiahGLavertuPNPhase II Trial of Sorafenib in patients with advanced anaplastic carcinoma of the thyroidThyroid201323560060423113752
   PubMed Web of Science ®Google Scholar
• BayerNexavar® versus placebo in locally advanced/metastatic RAI-refractory differentiated thyroid cancer Available from: http://www.clinicaltrials.gov/ct2/show/NCT00984282. NLM identifier: NCT00984282. Available form: www.clinicaltrials.gov/ct2/show/NCT00984282Accessed July 20, 2013
   Google Scholar
• PerriFLorenzoGDScarpatiGDBuonerbaCAnaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic optionsWorld J Clin Oncol20112315015721611089
   PubMedGoogle Scholar
• SmallridgeRCAinKBAsaSLAmerican Thyroid Association Anaplastic Thyroid Cancer Guidelines TaskforceThyroid201211221111043923130564
   PubMed Web of Science ®Google Scholar
• CooneyMMvan HeeckerenWBhaktaSOrtizJRemickSCDrug insight: vascular disrupting agents and angiogenesis – novel approaches for drug deliveryNat Clin Pract Oncol200631268269217139319
   PubMedGoogle Scholar
• HaHTLeeJSUrbaSA phase II study of imatinib in patients with advanced anaplastic thyroid cancerThyroid201020997598020718683
   PubMed Web of Science ®Google Scholar
• JinNJiangTRosenDMNelkinBDBallDWDual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancerJ Clin Endocrinol Metab200994104107411219723757
   PubMed Web of Science ®Google Scholar
• CatalanoMGFortunatiNPuglieseMHistone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cellsJ Clin Endocrinol Metab2012977E1150E115922563106
   PubMed Web of Science ®Google Scholar
• PapewalisCWuttkeMSchinnerSRole of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancerHorm Metab Res2009411075275619513966
   PubMed Web of Science ®Google Scholar
• O’NeillJPShahaARAnaplastic thyroid cancerOral Oncol201349770270623583302
   PubMed Web of Science ®Google Scholar
• ItoKHanamuraTMurayamaKMultimodality therapeutic outcomes in anaplastic thyroid carcinoma: improved survival in subgroups of patients with localized primary tumorsHead Neck201234223023721500309
   PubMed Web of Science ®Google Scholar
• GranataRLocatiLLicitraLTherapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literatureCurr Opin Oncol201325322422823493194
   PubMed Web of Science ®Google Scholar
• SosaJAEliseiRJarzabBA randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trialJ Clin Oncol201129Suppl Abstr 5502. Available from: http://meetinglibrary.asco.org/content/78227-102Accessed July 20, 2013
   Google Scholar
• PierieJPMuzikanskyAGazRDFaquinWCOttMJThe effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinomaAnn Surg Oncol2002Jan-Feb91576411833496
   PubMed Web of Science ®Google Scholar
• KimSPrichardCNYounesMNCetuximab and Irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude miceClin Cancer Res2006115122600716428506
   PubMed Web of Science ®Google Scholar